BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38297040)

  • 1. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT.
    Beksac M; Eikema DJ; Koster L; Hulin C; Poiré X; Hamladji RM; Gromek T; Bazarbachi A; Ozkurt ZN; Pabst T; Ben Othman T; Finke J; Pirogova O; Wu D; Hayat A; Hilgendorf I; Tholouli E; de Wreede LC; Schönland S; Garderet L; Drozd-Sokolowska J; Raj K; Hayden PJ; Yakoub-Agha I; McLornan DP
    Bone Marrow Transplant; 2024 Apr; 59(4):526-533. PubMed ID: 38297040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
    Sidana S; Kumar S; Fraser R; Estrada-Merly N; Giralt S; Agrawal V; Anderson LD; Aljurf M; Banerjee R; Bashey A; Battiwalla M; Beitinjaneh A; Chakraborty R; Chhabra S; Dhakal B; Dholaria B; Hashmi S; Janakiram M; Lee C; Lekakis L; Murthy HS; Parrondo R; Wangjam T; Usmani S; Shah N; Qazilbash M; D'Souza A
    Transplant Cell Ther; 2022 Feb; 28(2):83.e1-83.e9. PubMed ID: 34781066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
    Khan AM; Yucebay F; Zhao Q; Umyarova E; Cottini F; Bumma N; Rosko A; Benson D; Sharma N; Efebera Y; Devarakonda S
    Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e85-e96. PubMed ID: 36411211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT.
    Beksac M; Iacobelli S; Koster L; Cornelissen J; Griskevicius L; Rabin NK; Stoppa AM; Meijer E; Mear JB; Zeerleder S; Mayer J; Fenk R; Fegueux N; Chevallier P; Konirova E; Snowden JA; Engelhardt M; Orchard K; Hulin C; Schaap N; Sossa C; Elmaagacli A; McLornan DP; Hayden PJ; Schönland S; Yakoub-Agha I
    Bone Marrow Transplant; 2023 Aug; 58(8):916-923. PubMed ID: 37160942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma.
    Huang J; Phillips S; Byrne M; Chinratanalab W; Engelhardt BG; Goodman SA; Harrell SL; Jagasia M; Kassim A; Rawling KT; Savani BN; Sengsayadeth S; Cornell RF
    Bone Marrow Transplant; 2018 Jun; 53(6):701-707. PubMed ID: 29703965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma.
    Straka C; Salwender H; Knop S; Vogel M; Müller J; Metzner B; Langer C; Sayer H; Jung W; Dürk HA; Bassermann F; Gramatzki M; Rösler W; Wolf HH; Brugger W; Engelhardt M; Fischer T; Liebisch P; Einsele H
    Eur J Haematol; 2021 Nov; 107(5):529-542. PubMed ID: 34270825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance.
    Gaballa MR; Ma J; Tanner MR; Al-Juhaishi T; Bashir Q; Srour SA; Saini NY; Ramdial JL; Nieto Y; Murphy R; Rezvani K; Tang G; Lee HC; Patel KK; Kaufman GP; Manasanch EE; Ullah MR; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Leuk Lymphoma; 2022 Mar; 63(3):710-721. PubMed ID: 34686083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen.
    Hagen P; D'Souza A; Hari P; Davila O; Zhang MJ; Vesole DH; Smith SE; Rodriguez TE; Stiff PJ
    Leuk Lymphoma; 2020 Dec; 61(14):3484-3492. PubMed ID: 32865474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.
    Stadtmauer EA; Pasquini MC; Blackwell B; Hari P; Bashey A; Devine S; Efebera Y; Ganguly S; Gasparetto C; Geller N; Horowitz MM; Koreth J; Knust K; Landau H; Brunstein C; McCarthy P; Nelson C; Qazilbash MH; Shah N; Vesole DH; Vij R; Vogl DT; Giralt S; Somlo G; Krishnan A
    J Clin Oncol; 2019 Mar; 37(7):589-597. PubMed ID: 30653422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
    Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
    Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib-based induction therapy followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients: A single-center experience and review of Indian literature.
    Kathrotiya M; Radhakrishnan V; Bhave SJ; Nag A; Arora N; Roychoudhry M; Parihar M; Mishra D; Nair R; Chandy M; Kumar J
    Indian J Cancer; 2023 Oct; 60(4):486-492. PubMed ID: 38258869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).
    Roussel M; Moreau P; Huynh A; Mary JY; Danho C; Caillot D; Hulin C; Fruchart C; Marit G; Pégourié B; Lenain P; Araujo C; Kolb B; Randriamalala E; Royer B; Stoppa AM; Dib M; Dorvaux V; Garderet L; Mathiot C; Avet-Loiseau H; Harousseau JL; Attal M;
    Blood; 2010 Jan; 115(1):32-7. PubMed ID: 19884643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory analysis of intensified conditioning as first line treatment for patients with high risk multiple myeloma.
    Bommier C; Talbot A; Harel S; Cuccuini W; Gérard L; Arnulf B
    Hematol Oncol; 2020 Oct; 38(4):517-522. PubMed ID: 32569436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care.
    Bostankolu Değirmenci B; Yegin ZA; Akdemir ÜÖ; Dede A; Gündem GG; Özkurt ZN; Atay LÖ; Yağcı M
    Ann Hematol; 2024 Jan; 103(1):269-283. PubMed ID: 37880484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation.
    Xu T; Yang Y; Li J; Xu J; Wang W; Wang Y; Maihemaiti A; Ren L; Lan T; Zhou C; Li P; Wang P; Liu P
    Ann Hematol; 2023 May; 102(5):1171-1184. PubMed ID: 36882560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
    Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Allotey D; Shafeek S; Jenner MW; Cook G; Russell NH; Kaiser MF; Drayson MT; Owen RG; Gregory WM; Morgan GJ; Clinical Studies Group UNHO
    Haematologica; 2021 Jul; 106(7):1957-1967. PubMed ID: 32499244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma.
    Barta SK; Jain R; Mazumder A; Carter J; Almanzar L; Browne R; Shahnaz S; Elkind R; Kaminetzky D; Battini R; Derman O; Kornblum N; Verma A; Braunschweig I
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):650-657. PubMed ID: 28684379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.